KHN-921 gains IND clearance for MYBPC3-associated HCM

May 14, 2026

Chengdu Origen Biotechnology Co. Ltd. and Vanotech Ltd. have announced IND clearance by the FDA for KHN-921 for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations.

BioWorld Science Regulatory Cardiovascular Gene therapy FDA IND

Today's news in brief

BioWorld

BioWorld briefs for May 15, 2026.

Illustration of a glowing circle to represent circRNA

ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

BioWorld

Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...

Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

BioWorld

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

3D illustration of adeno-associated viruses

ASGCT 2026: Uncovering the mechanisms of AAV toxicity

BioWorld

Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...